INIS - International Isotopes, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
-0.003 (-3.37%)
At close: 11:45AM EDT
Stock chart is not supported by your current browser
Previous Close0.089
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.000 - 0.000
52 Week Range
Avg. Volume103,267
Market Cap35.099M
PE Ratio (TTM)N/A
EPS (TTM)-0.009
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.12
Trade prices are not sourced from all markets
  • PR Newswire2 months ago

    International Isotopes Inc. Announces 2017 Year End Financial Results

    IDAHO FALLS, Idaho, April 2, 2018 /PRNewswire/ -- International Isotopes Inc. (INIS) (the "Company") announces its financial results for the fiscal year ended December 31, 2017.  The Company reported total revenue in 2017 of $7,420,390, compared to $6,552,149 in 2016, which represents an increase of approximately 13%.  The details of the performance of the Company's significant business segments are discussed below.

  • PR Newswire6 months ago

    International Isotopes Inc. Announces Third Quarter And Nine-Month 2017 Financial Results

    IDAHO FALLS, Idaho, Nov. 15, 2017 /PRNewswire/ -- International Isotopes Inc. (INIS) (the "Company") announces financial results for the third quarter and nine months ended September 30, 2017. Revenue for the nine-month period ended September 30, 2017 was $5,520,733, as compared to $4,801,672 for the same period in 2016, an increase of $719,061, or approximately 15%. This increase in revenue for both the three- and nine-month periods was largely the result of increases in both the radiochemical and radiological services segments.

  • PR Newswire8 months ago

    International Isotopes Inc. Announces Dr. Robert Atcher Has Joined The Company Board of Directors

    IDAHO FALLS, Idaho, Sept. 6, 2017 /PRNewswire/ -- International Isotopes Inc. (INIS) (the "Company" or "INIS") has announced that Dr. Robert W. Atcher, PhD, MBA, FSNMMI has accepted a position on the Company's Board of Directors. Dr. Atcher is a radiopharmaceutical chemist who has focused his work on diagnosis and treatment of cancer and heart disease.  His experience ranges from the production and separation of radionuclides, production and purification of radiopharmaceuticals, preclinical testing, and clinical trials of radiopharmaceuticals.   He graduated from Washington University in St. Louis with a degree in Chemistry, received his PhD from the University of Rochester in Nuclear Chemistry, and his postdoctoral training was done at Harvard Medical School in Boston.

  • PR Newswire9 months ago

    International Isotopes Inc. Announces It Has Assumed Management of RadQual, LLC

    A Buying Group Has Purchased All Of The Member Shares Of RadQual Not Owned By INIS. IDAHO FALLS, Idaho, Aug. 21, 2017 /PRNewswire/ -- International Isotopes Inc. (INIS) (the "Company" or "INIS") announced that a group of buyers has acquired all the units of RadQual, LLC ("RadQual") not already held by INIS.  The buying group is comprised of a group of affiliates of the Company, including the current Chairman of the Board, the former Chairman of the Board, and the Chief Executive Officer of the Company.  This group has acquired approximately 75% of the member units of RadQual.  INIS still retains its 25% ownership in RadQual.

  • PR Newswire9 months ago

    International Isotopes Inc. Announces Financial Results For The Second Quarter And Six Months Ended June 30, 2017

    IDAHO FALLS, Idaho, Aug. 16, 2017 /PRNewswire/ -- International Isotopes Inc. (INIS) announces its financial results for the second quarter and six months ended June 30, 2017. Revenue from nuclear medicine products for the three months and six months ended June 30, 2017 decreased about 1% compared to the same periods in 2016.

  • PR Newswire9 months ago

    International Isotopes Inc. Obtains Significant Additional Radiological Field Service Contracts

    IDAHO FALLS, Idaho, Aug. 9, 2017 /PRNewswire/ -- International Isotopes Inc. (INIS) (the "Company") announces that it has obtained several significant contracts for Radiological Field Services that are to be completed during the remainder of 2017.  The Company reports these contracts are both with the U.S. Department of Energy (DOE) and the International Atomic Energy Agency (IAEA) for work within the U.S. and in South America.  All of the contract work will involve performing source removals from inactive radiation therapy devices and shipping these devices to secure locations for storage and disposal.